Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease
Spironolactone for Heart Failure with Preserved Ejection Fraction
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension
Spironolactone Reduces the Risk of Death in Veterans With Heart Failure With Preserved Ejection Fraction
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART pooled analysis of cardiovascular, kidney, and mortality outcomes
Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial
Effects of the Non-Steroidal MRA Finerenone with and without Concomitant SGLT2 Inhibitor Use in Heart Failure
Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: a Prespecified Analysis of The FINEARTS-HF Trial
Finerenone Improves Outcomes in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF
New ways of mitigating aldosterone in cardiorenal disease
Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial
Mineralocorticoid Receptor Antagonists in Heart Failure: An Update
Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A <span style="font-variant:small-caps;">FIDELITY</span> analysis
Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial
Efficacy and Tolerability of Finerenone According to the Use and Dosage of Diuretics: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial
Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved ejection fraction: Findings from <span style="font-variant:small-caps;">FINEARTS</span> ‐ <span style="font-variant:small-caps;">HF</span>
Nonsteroidal Versus Steroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Real‐World Evidence From a Multicenter Cohort Study
